JP2024513835A5 - - Google Patents

Info

Publication number
JP2024513835A5
JP2024513835A5 JP2023560404A JP2023560404A JP2024513835A5 JP 2024513835 A5 JP2024513835 A5 JP 2024513835A5 JP 2023560404 A JP2023560404 A JP 2023560404A JP 2023560404 A JP2023560404 A JP 2023560404A JP 2024513835 A5 JP2024513835 A5 JP 2024513835A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
antigen
binding domain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023122 external-priority patent/WO2022212885A1/en
Publication of JP2024513835A publication Critical patent/JP2024513835A/ja
Publication of JP2024513835A5 publication Critical patent/JP2024513835A5/ja
Pending legal-status Critical Current

Links

JP2023560404A 2021-04-02 2022-04-01 抗muc16×抗cd3二重特異性抗体を含有する安定化製剤 Pending JP2024513835A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163170320P 2021-04-02 2021-04-02
US63/170,320 2021-04-02
US202263313927P 2022-02-25 2022-02-25
US63/313,927 2022-02-25
PCT/US2022/023122 WO2022212885A1 (en) 2021-04-02 2022-04-01 Stabilized formulations containing anti-muc16 x anti-cd3 bispecific antibodies

Publications (2)

Publication Number Publication Date
JP2024513835A JP2024513835A (ja) 2024-03-27
JP2024513835A5 true JP2024513835A5 (https=) 2025-04-08

Family

ID=81579790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560404A Pending JP2024513835A (ja) 2021-04-02 2022-04-01 抗muc16×抗cd3二重特異性抗体を含有する安定化製剤

Country Status (13)

Country Link
US (1) US20220332849A1 (https=)
EP (1) EP4313008A1 (https=)
JP (1) JP2024513835A (https=)
KR (1) KR20230165828A (https=)
AU (1) AU2022246687A1 (https=)
BR (1) BR112023019096A2 (https=)
CA (1) CA3213546A1 (https=)
CL (1) CL2023002922A1 (https=)
CO (1) CO2023014918A2 (https=)
IL (1) IL306042A (https=)
MX (1) MX2023011469A (https=)
TW (1) TW202304507A (https=)
WO (1) WO2022212885A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7066690B2 (ja) * 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗muc16(ムチン16)抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
NZ609557A (en) * 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2016036678A1 (en) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗muc16(ムチン16)抗体

Similar Documents

Publication Publication Date Title
KR102397713B1 (ko) 안정한 액체 약제학적 제제
JP2024016177A5 (https=)
FI4249512T3 (fi) Stabiili vasta-aineformulaatio
JP2020518600A5 (https=)
WO2020094122A1 (zh) 一种TGF-β受体融合蛋白药物组合物及其用途
JP7278952B2 (ja) 安定化された抗体タンパク質溶液
JP2009507838A (ja) 抗cd3抗体製剤
JP2016534052A5 (https=)
JP2022532927A5 (https=)
JP2023071755A (ja) 安定化された抗体溶液
JP2024544523A5 (https=)
JP2024513835A5 (https=)
WO2010132872A1 (en) Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
JP2025502061A5 (https=)
JP2023507561A5 (https=)
US20240409631A1 (en) Aqueous formulations of an anti-cd22 antibody and uses thereof
JP2023533963A5 (https=)
US20250345422A1 (en) Pharmaceutical compositions of a pd-1 antibody and use of the same
RU2024122332A (ru) СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕГО РАКА ЯИЧНИКА С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХ АНТИТЕЛ К MUC16 x CD3 ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ К PD-1
JP2021518393A5 (https=)
JP2024535041A5 (https=)
EA045933B1 (ru) Водная фармацевтическая композиция левилимаба и ее применение
HK40045548A (en) TGF-β RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF
RU2018108050A (ru) 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака
RU2021106602A (ru) 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака